NEXT-GENERATION RNA THERAPEUTICS: INTELLIGENT TARGETED DELIVERY PLATFORMS AND THEIR PHARMACOLOGICAL IMPLICATIONS

Abstract

Abstract: RNA therapeutics have emerged as one of the most transformative innovations in modern molecular medicine, enabling precise modulation of gene expression for the treatment of various acute and chronic diseases. Unlike conventional pharmacotherapy, which primarily targets proteins and downstream signaling pathways, RNA-based therapeutics act upstream at the genetic and transcriptomic levels, offering superior specificity, adaptability, and therapeutic potential. Recent advancements in messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides (ASOs), aptamers, circular RNA (circRNA), and CRISPR-associated RNA technologies have revolutionized disease management strategies. However, the successful clinical translation of RNA therapeutics has historically been constrained by poor stability, enzymatic degradation, limited cellular uptake, rapid systemic clearance, immunogenicity, and inadequate tissue-specific targeting. To overcome these challenges, intelligent targeted delivery systems have been developed, including lipid nanoparticles (LNPs), polymeric nanoparticles, exosome-mediated delivery, viral vectors, ligand-conjugated carriers, cell-penetrating peptides, and stimuli-responsive nanoplatforms. These advanced delivery technologies significantly improve RNA bioavailability, cellular internalization, pharmacokinetic behavior, tissue specificity, and therapeutic efficacy while minimizing systemic toxicity. Moreover, the integration of artificial intelligence (AI), machine learning, and precision nanomedicine is accelerating the optimization of RNA delivery strategies and personalized therapeutic interventions. RNA therapeutics demonstrate immense pharmacological implications in oncology, cardiovascular disorders, neurological diseases, infectious diseases, metabolic syndromes, and rare genetic disorders. Despite remarkable progress, several limitations related to safety, regulatory approval, manufacturing complexity, and long-term efficacy remain unresolved. This review comprehensively discusses next-generation RNA therapeutics, emerging intelligent delivery platforms, pharmacological implications, clinical applications, safety concerns, and future perspectives, emphasizing their transformative role in precision medicine and targeted therapeutics.